The Efficacy and Safety of Vardenafil in East Asian Men with Erectile Dysfunction

Chen, Kuang-Kuo; Paick, Jae‐Seung; Ishii, Nobuhisa

doi:10.1111/j.1743-6109.2007.00468.x

Cited by 16 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, which contained a high percentage of Asian subjects (43.8%), vardenafil treatment was associated with favourable outcomes for effectiveness, safety and relationship quality. This echoes the findings of a previous study, which demonstrated the excellent efficacy and tolerability of vardenafil in a population of exclusively East Asian men [30]. There are some limitations to this study.…”

Section: Patientssupporting

confidence: 88%

The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study

2014

View full text Add to dashboard Cite

This study assessed the improvement in relationship quality, effectiveness and safety associated with vardenafil for the treatment of erectile dysfunction (ED). The study was conducted in 1433 centres across 21 countries and comprised a baseline patient visit and up to four follow-up visits during an observational period of 1 year. Relationship quality, happiness, satisfaction with vardenafil treatment, and safety and tolerability were assessed by physician interviews and patient and partner questionnaires. Overall, 7496 patients were enrolled in the study, of which 7430 were included in the safety analyses and 6470 in the effectiveness analyses. Relationship quality, assessed by a relationship questionnaire (partnerschaftsfragebogen [PFB]), was improved at last observation carried forward, compared with baseline, in both patients and partners and satisfaction with the effectiveness of vardenafil treatment was high. Vardenafil was well tolerated and adverse events were consistent with the known safety profile of phosphodiesterase type 5 inhibitors. These results confirm the well-established effectiveness and safety profiles of vardenafil. This study is the first to demonstrate improvements in relationship quality following vardenafil therapy, in both patients and partners, using the PFB questionnaire.

show abstract

Section: Patientssupporting

confidence: 88%

The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study

2014

View full text Add to dashboard Cite

show abstract

“…For patients experiencing ED, first-line therapy typically includes one or more trials with a phosphodiesterase-5 inhibitor (PDE5i). These agents result in successful penetrative intercourse in the order of 80% [5][6][7][8][9] .…”

Section: Introductionmentioning

confidence: 98%

Prediction model for penile prosthesis implantation for erectile dysfunction management

Segal

Camper

et al. 2014

Current Medical Research and Opinion

View full text Add to dashboard Cite

The presence and extent of specific medical history factors at the time of erectile dysfunction diagnosis predict an individual's future likelihood of penile prosthesis. Calculating the likelihood of penile prosthesis implantation based on the weight of these factors may assist clinicians with the definition of a care plan and patient counseling. The precision of the model may be limited by factors beyond medical history information that possibly influence the decision to proceed to surgery.

show abstract

“…36 Treatment with vardenafil produced significant improvement in the main efficacy measures of IIEF-EF score and SEP2 and SEP3 as well as the GAQ. The efficacy [31][32][33][34][35][36][37][38][39][40][41][42][43][44] Prevalence and management of ED in Asia K Park et al 547…”

Section: Efficacy and Safety Of Sildenafilmentioning

confidence: 99%

“…These included four RCTs of sildenafil, [31][32][33][34] two RCTs of vardenafil, 35,36 four RCTs of tadalafil, [37][38][39][40] two RCTs of udenafil 41,42 and two RCTs of mirodenafil. 43,44 The efficacy and safety of two novel PDE-5 inhibitors, mirodenafil and udenafil, were evaluated only in Korean men.…”

Section: Medical Treatment Of Ed In Asiamentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and medical management of erectile dysfunction in Asia

Park¹,

Hwang²,

Kim³

2011

Asian J Androl

View full text Add to dashboard Cite

Erectile dysfunction (ED) is an important worldwide health issue that has a significant negative impact on the quality of life and life satisfaction of both the affected individual and his partner. Here we review the prevalence of ED in Asia, associated factors that may influence sexual attitudes and sexual behaviours, and randomized clinical trials (RCTs) of phosphodiesterase-5 (PDE-5) inhibitors to evaluate the clinical efficacy and safety of PDE-5 inhibitors in Asian men. We searched for English-language articles in MEDLINE and PubMed from January 2000 to September 2010. Our results showed that the overall reported prevalence rate of ED in Asia ranged widely, from 2% to 88%. This finding indicates that ED is a common and major health problem in this region. However, sociocultural and economic factors in Asia prevent people from seeking and obtaining appropriate medical care. We found reports on five kinds of PDE-5 inhibitors for the management of ED: sildenafil, vardenafil, tadalafil, udenafil and mirodenafil. The results of RCTs showed that these five PDE-5 inhibitors are more effective than placebo in improving erectile function in Asian men with ED and that these drugs have similar efficacy and safety profiles. INTRODUCTIONErectile dysfunction (ED) has been defined as the inability to achieve or maintain an erection sufficiently rigid for achieving satisfying sexual intercourse.1 ED is an important worldwide health issue that affects nearly half of men over the age of 40 years, and it has a significant negative impact on the quality of life and life satisfaction of the affected individual as well as his partner.2,3 One of the most frequently cited epidemiological surveys reporting prevalence data for ED is the Massachusetts Male Aging Study.2 The Massachusetts Male Aging Study-the first longitudinal, community-based, randomized, widescale epidemiological study of ED-included 1709 men between the ages of 40 and 70 years who completed a self-reported ED questionnaire. Over that age range, the probabilities of minimal, moderate and complete ED were 16.5%, 17.5% and 4.9%, respectively, at age of 40 years, and 18%, 34% and 15% at age of 70 years, showing that the prevalence of ED increases with age.Another pivotal epidemiological study of sexual dysfunction was the Global Study of Sexual Attitudes and Behaviors (GSSAB), which included 27 500 men and women aged 40-80 years in 29 countries.

show abstract

The Efficacy and Safety of Vardenafil in East Asian Men with Erectile Dysfunction

Cited by 16 publications

References 28 publications

The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study

The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study

Prediction model for penile prosthesis implantation for erectile dysfunction management

Prevalence and medical management of erectile dysfunction in Asia

Contact Info

Product

Resources

About